Scientist, Signal Transduction and Cancer Biology

1910 Genetics

20n Bio

3DBio Therapeutics

3T Biosciences

4D Molecular Therapeutics

64x Bio

76Bio

A-Alpha Bio

A2 Biotherapeutics

ACELYRIN

AI Proteins

AIRNA Bio

ALX Oncology

AN2 Therapeutics

AOA Dx

ARTBIO

AUM BioTech

AVROBIO

Ab Studio

Abalone Bio

Abata Therapeutics

Abeona Therapeutics

Abintus Bio

Abiosciences

Absci

Accelevir Diagnostics

Accent Therapeutics

Acepodia

Achieve Life Sciences

Acrivon Therapeutics

Acutis Diagnostics

Adaptive Phage Therapeutics

Adcentrx Therapeutics

Adicet Bio

Aditum Bio

Admera Health

Adverum Biotechnologies

Aeglea BioTherapeutics

Aether Bio

Affini-T Therapeutics

Affinia Therapeutics

Affinivax

AgBiome

Agena Bioscience

Akero Therapeutics

Akouos

Alamar Biosciences

Alector

AlivaMab Discovery Services

Alkahest

Alladapt Immunotherapeutics

Allakos

Allarta Life Science

Allay Therapeutics

AlloVir

Alloy Therapeutics

Alltrna

AlpaLifeBio

Alpha-9 Oncology

Alphabioregen

Alpine Immune Sciences

AltPep

Altis Biosystems

Alto Neuroscience

Alumis

Alveo Technologies

Alveolus Bio

Alzheon

AmbAgon Therapeutics

Amberstone Biosciences

Amolyt Pharma

Amylyx Pharmaceuticals

AnHeart Therapeutics

Anagram Therapeutics

Andes

Angiex

Angiocrine Bioscience

Annexon Biosciences

Anokion

Ansa Biotechnologies

Antheia

Anthos Therapeutics

Apollomics

Appia Bio

Apriori Bio

Aptevo Therapeutics

Aptose Biosciences

Aquinnah Pharmaceuticals

Aramis Biosciences

Arbor Biotechnologies

Arc Institute

Arcadia Science

Arcellx

Arctoris

Arcturus Therapeutics

Arcutis Biotherapeutics

Arima Genomics

Ark Biotech

Arkuda Therapeutics

Armata Pharmaceuticals

Acrivon Therapeutics is using a proteomics-based approach to develop precision oncology therapeutics. While the underlying basis of cancer is genomic alterations, it is the dysregulated proteome that drives the disease. Proteomic biomarkers therefore offer a more accurate matching of patients with drugs than genomic biomarkers. Acrivon is using their proprietary Predictive Precision Proteomics platform to develop patient selection tumor biopsy tests, called OncoSignature® tests, to identify which patients will benefit from a specific drug, matching drug mechanisms to the biologic drivers of cancer. Acrivon’s clinical pipeline is currently focused on advanced assets targeting the DNA damage response where traditional patient selection is challenging, with Phase 2 trials initiated.

<p>Acrivon Therapeutics is using a proteomics-based approach to develop precision oncology therapeutics. While the underlying basis of cancer is genomic alterations, it is the dysregulated proteome that drives the disease. Proteomic biomarkers therefore offer a more accurate matching of patients with drugs than genomic biomarkers. Acrivon is using their proprietary Predictive Precision Proteomics platform to develop patient selection tumor biopsy tests, called OncoSignature® tests, to identify which patients will benefit from a specific drug, matching drug mechanisms to the biologic drivers of cancer. Acrivon’s clinical pipeline is currently focused on advanced assets targeting the DNA damage response where traditional patient selection is challenging, with Phase 2 trials initiated.</p>


Find a biotech startup job.